Clinical Trials
26 trialsNCT03414229 2026-04-23
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03516708 2026-02-11
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Washington University School of Medicine
Phase 1/2 Recruiting
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT03006302 2024-10-08
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03291054 2024-06-11
Epacadostat and Pembrolizumab in Patients With GIST
Columbia University
Phase 2 Terminated
NCT03196232 2024-01-23
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Stanford University
Phase 2 Completed
NCT03823131 2023-05-09
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
University of California, San Francisco
Phase 2 Terminated
NCT03217669 2023-05-03
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
University of Kansas Medical Center
Phase 1 Unknown
NCT02166905 2023-02-24
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT03592407 2022-03-08
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT03322384 2022-02-01
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
University of California, Davis
Phase 1/2 Completed
NCT03471286 2021-08-26
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT03832673 2021-02-26
PECULIAR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Withdrawn
NCT04231864 2020-10-26
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT03707457 2020-07-02
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT03463161 2020-01-27
ORKA
University of Chicago
Phase 2 Terminated
NCT02364076 2019-12-13
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
Georgetown University
Phase 2 Unknown
NCT03432676 2019-05-30
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03325465 2019-04-22
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Withdrawn
NCT03402880 2018-10-10
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT03182894 2018-08-28
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 1/2 Withdrawn
NCT01961115 2018-06-08
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT03238638 2018-01-04
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
University of Chicago
Phase 2 Withdrawn
NCT02118285 2017-12-05
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01822691 2016-01-18
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01982487 2013-12-18
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Roswell Park Cancer Institute
Phase 1/2 Withdrawn